ROVI updates its strategy in a meeting with shareholders, investors and analysts
Wed, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Related
ROVI takes first place in the Sustainalytics world ESG risk ranking for the second year running
Laboratorios Farmacéuticos...
3 min
04/08/2023
ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®
The United States Food and Drug Administration (...
1 min
28/07/2023
ROVI ACHIEVED STABLE TOTAL REVENUE OF 381.0 MILLION EUROS IN THE FIRST POST-PANDEMIC HALF YEAR
Operating revenue remained stable,...
4 min
26/07/2023
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.